← Leaderboards
Kendall A Smith
Weill Medical College Of Cornell Univ
$14,630,665
Attributed
$14,630,665
Total exposure
12
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2005–10$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$14,630,665 · 12
By mechanism
U01$8,279,936 · 2
R01$3,785,478 · 4
M01$2,565,251 · 6
Top collaborators
No co-investigators on record.
Most similar at Weill Medical College Of Cornell Univ
Same institution · by research overlap
- John P Moore$51,152,802
- Ronald G Crystal$80,684,359
- Bruce R Schackman$21,876,043
- Min Lu$17,094,037
- James M Binley$18,370,920
Others in their field
Top investigators on “Interleukin 2”
- Richard L Schilsky · University Of Chicago$50,043,295
- Kent J. Weinhold · Duke University$39,902,311
- Prescott G Woodruff · University Of California San Francisco$38,441,989
- Joren C Madsen · Massachusetts General Hospital$31,981,782
- Vijay K Kuchroo · Brigham And Women'S Hospital$30,356,719
- Donald Ym Leung · University Of Colorado Denver$29,922,955
Research focus
Interleukin 2Human SubjectClinical ResearchHuman Therapy EvaluationImmunotherapyAids TherapyT LymphocyteHiv InfectionsHelper T LymphocyteProtein BiosynthesisFlow CytometryClinical TrialsCytokineTumor Necrosis Factor AlphaHepatitis C VirusHuman Immunodeficiency VirusImmune ResponseHepatitis CDrug Administration Rate /DurationLeukocyte Activation /TransformationGene ExpressionCellular ImmunityMicroorganism Disease ChemotherapyRecombinant Proteins
Grant awards (34)
New Strategies to Prevent Death from Influenza$1,196,788
U01 · FY2010 · AI · contact PI
New Strategies to Prevent Death from Influenza$1,176,371
U01 · FY2009 · AI · contact PI
New Strategies to Prevent Death from Influenza$1,144,813
U01 · FY2008 · AI · contact PI
New Strategies to Prevent Death from Influenza$1,135,759
U01 · FY2007 · AI · contact PI
ULTRA LOW DOSE RECOMBINANT IL-2 IN HEPATITIS C VIRUS DISEASE$50
M01 · FY2007 · RR · contact PI
New Strategies to Prevent Death from Influenza$1,440,342
U01 · FY2006 · AI · contact PI
Hiv Immune Reactivity 'in Vivo' and 'In Vitro'$413,792
R01 · FY2006 · AI · contact PI
TRIAL/ EFFICACY OF IMMUNOTHERAPIES TO CONTROL PLASMA HIV RNA INTERRUP HAART$47,507
M01 · FY2006 · RR · contact PI
ULTRA LOW DOSE RECOMBINANT IL-2 IN HEPATITIS C VIRUS DISEASE$43,753
M01 · FY2006 · RR · contact PI
TRIAL/ EFFICACY OF IMMUNOTHERAPIES TO CONTROL PLASMA HIV RNA INTERRUP HAART$469,410
M01 · FY2005 · RR
Hiv Immune Reactivity 'in Vivo'and 'In Vitro'$423,750
R01 · FY2005 · AI
ULTRA LOW DOSE RECOMBINANT IL-2 IN HEPATITIS C VIRUS DISEASE$254,347
M01 · FY2005 · RR
Trial/ efficacy of immunotherapies to control plasma HIV RNA interrup HAART$1,352,541
M01 · FY2004 · RR
INTERLEUKIN 2 IMMUNOTHERAPY FOR HCV INFECTION$474,931
U01 · FY2004 · AI
Hiv Immune Reactivity 'in Vivo'and 'In Vitro'$423,750
R01 · FY2004 · AI
Ultra low dose recombinant IL-2 in hepatitis C virus disease$159,068
M01 · FY2004 · RR
INTERLEUKIN 2 IMMUNOTHERAPY FOR HCV INFECTION$457,787
U01 · FY2003 · AI
Hiv Immune Reactivity 'in Vivo'and 'In Vitro'$423,750
R01 · FY2003 · AI
T CELL CYCLE REGULATION BY CYTOKINE-RESPONSIVE GENES$256,254
R01 · FY2003 · AI
Hiv Immune Reactivity 'in Vivo'and 'In Vitro'$423,750
R01 · FY2002 · AI
INTERLEUKIN 2 IMMUNOTHERAPY FOR HCV INFECTION$390,814
U01 · FY2002 · AI
T CELL CYCLE REGULATION BY CYTOKINE-RESPONSIVE GENES$237,707
R01 · FY2002 · AI
INTERLEUKIN 2 IMMUNOTHERAPY FOR HCV INFECTION$438,581
U01 · FY2001 · AI
T CELL CYCLE REGULATION BY CYTOKINE-RESPONSIVE GENES$242,014
R01 · FY2001 · AI
PHASE I STUDY OF RECOMBINANT IL-2 IN ASYMPTOMATIC HIV POSITIVE INDIVIDUALS$0
M01 · FY2001 · RR
LOW DOSE INTERLEUKIN 2 IN HIV+ PATIENTS W/ LESS THAN 300 CD4+ T CELLS$0
M01 · FY2001 · RR
A CONTROLLED TRIAL OF INTERLEUKIN-2 IMMUNOTHERAPY IN EARLY HIV INFECTION$0
M01 · FY2001 · RR
INTERLEUKIN 2 IMMUNOTHERAPY FOR HCV INFECTION$423,750
U01 · FY2000 · AI
REGULATION OF T CELL PROLIFERATION$421,304
R01 · FY2000 · AI
TCR REPERTOIRE AND T CELL MEMORY IN HIV INFECTION$284,444
R01 · FY2000 · AI
T CELL CYCLE REGULATION BY CYTOKINE-RESPONSIVE GENES$234,963
R01 · FY2000 · AI
A CONTROLLED TRIAL OF INTERLEUKIN-2 IMMUNOTHERAPY IN EARLY HIV INFECTION$79,525
M01 · FY2000 · RR
LOW DOSE INTERLEUKIN 2 IN HIV+ PATIENTS W/ LESS THAN 300 CD4+ T CELLS$79,525
M01 · FY2000 · RR
PHASE I STUDY OF RECOMBINANT IL-2 IN ASYMPTOMATIC HIV POSITIVE INDIVIDUALS$79,525
M01 · FY2000 · RR